MedTrace Logo

Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)

NCT02195089 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2016-04-19

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and the safety of BLS-ILB-E710c for the the fertile women with Cervical Intraepithelial Neoplasia (CIN3).

Conditions

  • Cervical Intraepithelial Neoplasia

Interventions

DRUG

BLS_ILS_E710c 500mg

\- 2 capsules per day for 20 days (week 1,2,4 \& 8)

DRUG

BLS_ILB_710c 1000mg

\- 4 capsules per day for 20 days (week 1,2,4 \& 8)

DRUG

BLS_ILS_E710c 1500mg

\- 6 capsules per day for 8 weeks (week 1,2,4 \& 8)

Sponsors & Collaborators

  • BioLeaders Corporation

    lead INDUSTRY

Principal Investigators

  • Jae-Kwan Lee, MD, PhD · Korea University Guro Hospital

  • Tae Jin Kim, MD, PhD · Kwandong University College of Medicine Cheil Hospital

  • Jong Sup Park, MD, PhD · The Catholic University, Korea Seoul St Mary's Hospital

  • Chi-Heum Cho, MD, PhD · The Dongsan Medical Center of Keimyung University

  • Jong Hyeok Kim, MD, PhD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195089 on ClinicalTrials.gov